Specify a stock or a cryptocurrency in the search bar to get a summary
Valbiotis SAS
ALVALValbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France. Address: rue Paul Vatine, Périgny, France, 17180
Analytics
WallStreet Target Price
4.9 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALVAL
Dividend Analytics ALVAL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALVAL
Stock Valuation ALVAL
Financials ALVAL
Results | 2019 | Dynamics |